Literature DB >> 35849265

Differences in chemotaxis of human mesenchymal stem cells and cervical cancer cells.

Yizuo Song1, Ruyi Li1, Miaomiao Ye1, Chunyu Pan1, Lihong Zheng1, Zhi-Wei Wang2, Xueqiong Zhu3.   

Abstract

In the last decade, there has been a rapid expansion in tumor targeted therapy using mesenchymal stem cells (MSCs) based on their unique tropism towards cancer cells. Despite similarities in morphology, immunophenotype, and differential potent in vitro, MSCs originated from different tissues do not necessarily have equivalent biological behaviors. It is important to screen the most chemotactic MSCs to cancer cells. In this study, different MSCs were isolated from various human tissues including adipose, umbilical cord, amniotic membrane, and chorion. The chemotaxis of human MSCs to cervical cancer cells was measured by CCK-8, ELISA and Transwell invasion assays. Western blotting was performed to explore the underlying mechanisms. MSCs derived from distinct sources can be differently recruited to cervical cancer cells, among which chorion-derived MSC (CD-MSC) possessed the strongest tropic capacity. CXCL12 was found to be highly secreted by cervical cancer cells, in parallel with the expression of CXCR4 in all MSCs. CD-MSC displayed the highest level of CXCR4. These results indicated that CXCL12/CXCR4 pathway contributed to the different chemotaxis to cervical cancer cells of each MSCs. This study proposed that CD-MSC with the highest CXCR4 expression is a promising therapeutic vehicle for targeted therapy in cervical cancer.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  CXCL12; CXCR4; Cervical cancer; Chemotaxis; MSC; Mesenchymal stem cell

Year:  2022        PMID: 35849265     DOI: 10.1007/s10495-022-01749-6

Source DB:  PubMed          Journal:  Apoptosis        ISSN: 1360-8185            Impact factor:   5.561


  43 in total

1.  Cervical cancer prevention in China: a key to cancer control.

Authors:  Fanghui Zhao; Youlin Qiao
Journal:  Lancet       Date:  2019-03-09       Impact factor: 79.321

2.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

3.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.

Authors:  Hyuna Sung; Jacques Ferlay; Rebecca L Siegel; Mathieu Laversanne; Isabelle Soerjomataram; Ahmedin Jemal; Freddie Bray
Journal:  CA Cancer J Clin       Date:  2021-02-04       Impact factor: 508.702

Review 4.  Immunological aspects of allogeneic mesenchymal stem cell therapies.

Authors:  Matthew D Griffin; Thomas Ritter; Bernard P Mahon
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

5.  Rising Mortality Rate of Cervical Cancer in Younger Women in Urban China.

Authors:  Min Wei; Wei Zhou; Yongyi Bi; Hong Wang; Yu Liu; Zhi-Jiang Zhang
Journal:  J Gen Intern Med       Date:  2018-11-27       Impact factor: 5.128

Review 6.  Do cancer therapies damage the uterus and compromise fertility?

Authors:  Meaghan J Griffiths; Amy L Winship; Karla J Hutt
Journal:  Hum Reprod Update       Date:  2020-02-28       Impact factor: 15.610

7.  Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Wui-Jin Koh; Nadeem R Abu-Rustum; Sarah Bean; Kristin Bradley; Susana M Campos; Kathleen R Cho; Hye Sook Chon; Christina Chu; Rachel Clark; David Cohn; Marta Ann Crispens; Shari Damast; Oliver Dorigo; Patricia J Eifel; Christine M Fisher; Peter Frederick; David K Gaffney; Ernest Han; Warner K Huh; John R Lurain; Andrea Mariani; David Mutch; Christa Nagel; Larissa Nekhlyudov; Amanda Nickles Fader; Steven W Remmenga; R Kevin Reynolds; Todd Tillmanns; Stefanie Ueda; Emily Wyse; Catheryn M Yashar; Nicole R McMillian; Jillian L Scavone
Journal:  J Natl Compr Canc Netw       Date:  2019-01       Impact factor: 12.693

8.  Significant variations in the cervical cancer screening rate in China by individual-level and geographical measures of socioeconomic status: a multilevel model analysis of a nationally representative survey dataset.

Authors:  Heling Bao; Lei Zhang; Limin Wang; Mei Zhang; Zhenping Zhao; Liwen Fang; Shu Cong; Maigeng Zhou; Linhong Wang
Journal:  Cancer Med       Date:  2018-03-24       Impact factor: 4.452

9.  Estimates of incidence and mortality of cervical cancer in 2018: a worldwide analysis.

Authors:  Marc Arbyn; Elisabete Weiderpass; Laia Bruni; Silvia de Sanjosé; Mona Saraiya; Jacques Ferlay; Freddie Bray
Journal:  Lancet Glob Health       Date:  2019-12-04       Impact factor: 26.763

Review 10.  Ovarian damage from chemotherapy and current approaches to its protection.

Authors:  N Spears; F Lopes; A Stefansdottir; V Rossi; M De Felici; R A Anderson; F G Klinger
Journal:  Hum Reprod Update       Date:  2019-11-05       Impact factor: 15.610

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.